In vivo evaluation of radioiodinated 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3- phenylpropyl)-piperazine derivatives as new ligands for sigma receptor imaging using single photon emission computed tomography

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 10, 2006, Pages 2009-2015

  Hirata, Masahiko ^a   Mori, Tetsuya ^a   Soga, Seigo ^a   Umeda, Takuya ^a   Ohmomo, Yoshiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

123I; Imaging; Radiopharmaceutical; SA4503; Sigma receptor; SPECT

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 [2 (3,4 DIMETHOXYPHENYL)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE DERIVATIVE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ATROPINE; HALOPERIDOL; IODINE 125; NALOXONE; NICOTINE; PHENTOLAMINE; PIPERAZINE DERIVATIVE; PROPRANOLOL; RADIOPHARMACEUTICAL AGENT; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; SPIPERONE; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG UPTAKE; EX VIVO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; RADIOIODINATION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; AUTORADIOGRAPHY; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; IODINE RADIOISOTOPES; MALE; MICE; PIPERAZINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33749432418     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.2009     Document Type: Article

References (36)

1. Martin W. R., Eades C. E., Thompson J. A., Huppler R. E., Gilbert P. E., J. Pharmacol. Exp. Ther., 197, 517-532 (1976).
2. Walker J. M., Bowen W. D., Walker F. O., Matsumoto R. R., De Costa B. R., Rice K. C., Pharmacol. Rev., 423, 55-402 (1990).
3. Quirion R., Bowen W. D., Itzhak Y., Junien J. L., Rothman R. B., Su T. P., Tam S. W., Taylor D. P., Trends Neurosci., 10, 444-446 (1992).
4. Hellewell S. B., Bruce A., Feinstein G., Orringer J., Williams W., Bowen W. D., Eur. J. Pharmacol., 268, 9-18 (1994).
5. Wolfe S. A. Jr., Clup S. G., De Souza E. B., Endocrinology, 124, 1160-1172 (1988).
6. Su T. P., London E. D., Jaffe J. H., Science, 240, 219-221 (1988).
7. Brent P. J., Pang G. T., Eur. J. Pharmacol., 278, 151-160 (1995).
8. Vilner B. J., John C. S., Bowen W. D., Cancer Res., 55, 408-413 (1995).
9. Honner M., Moebius F. F., Flandorfer A., Knaus H.-G., Striessnig J., Kempner E., Glossmann H., Proc. Natl. Acad. Sci. U.S.A., 93, 8072-8077 (1996).
10. Pan, Y.-X. Mei J., Wan B.-L., Zukermann A., Pasternak G. W., J. Neurochem., 70, 2279-2285 (1998).
11. Prasad P. D., Li H. W., Fey Y.-J., Ganpathy M. E., Fujita T., Plumley L. H., Yang-Feng T. L., Leibach F. H., Ganapathy V., J. Neurochem., 70, 443-451 (1998).
12. Seth P., Fei Y. J., Li H. W., Huang W., Leibach F. H., Ganapathy V., J. Neurochem., 78, 922-931 (1998).
13. Itzak Y. (ed.), "The Sigma Receptors. Neuroscience Perspective Series," Academic Press, London, 1994.
14. Matsuno K., Kobayashi T., Tanaka M. K., Mita S., Eur. J. Pharmacol., 312, 267-271 (1996).
15. Maurice T., Lockhart A. A., Prog. Neuro-Psycopharmacol. Biol. Psychiat., 21, 69-102 (1997).
16. Nabeshima T., Okuyama S., Jpn. J. Psychopharmacol., 14, 51-76 (1994).
17. Amano M., Yamada K., Matsuno K., Nabeshima T., Jpn. J. Psychopharmacol., 16, 73-84 (1996).
18. Hayashi T., Su T. P., CNS Drugs, 18, 269-284 (2004).
19. John C. S., Gulden M. E., Vilner B. J., Bowen W. D., Nucl. Med. Biol., 23, 761-766 (1996).
20. Waterhouse R. N., Chapman J., Izard B., Donald A., Belbin K., O'Brien J. C., Collier T. L., Nucl. Med. Biol., 24, 587-593 (1997).
21. Waterhouse R. N., Mardon K., O'Brien J. C., Nucl. Med. Biol., 24, 45-51 (1997).
22. Waterhouse R. N., Collier T. L., Nucl. Med. Biol., 24, 127-134 (1997).
23. Dence C. S., John C. S., Bowen W. D., Welch M. J., Nucl. Med. Biol., 24, 333-340 (1997).
24. Ishiwata K., Noguchi J., Ishii S., Hatano K., Ito K., Nabeshima T., Senda M., Nucl. Med. Biol., 25, 195-202 (1998).
25. Kobayashi T., Matsuno K., Nakata K., Mita S., J. Pharmacol. Exp. Ther., 279, 106-113 (1996).
26. Matsuno K., Nakazawa M., Okamoto K., Kawashima Y., Mita S., Eur. J. Pharmacol., 306, 271-279 (1996).
27. Kawamura K., Ishiwata K., Tajima H., Ishii S., Matsuno K., Homma Y., Senda M., Nucl. Med. Biol., 27, 255-261 (2000).
28. Kawamura K., Ishiwata K., Shimada Y., Kimura Y., Kobayashi T., Matsuno K., Ann. Nucl. Med., 14, 285-292 (2000).
29. Kawamura K., Elsinga P. H., Kobayashi T., Ishii S., Wang W. F., Matsuno K., Vaalburg W., Ishiwata K., Nucl. Med. Biol., 30, 273-284 (2003).
30. Ishiwata K., Tsukada H., Kawamura K., Kimura Y., Nishiyama S., Kobayashi T., Synapse, 40, 235-237 (2001).
31. Kawamura K., Kimura Y., Tsukada H., Kobayashi T., Nishiyama S., Kakiuchi T., Ohba H., Harada N., Matsuno K., Ishii S., Ishiwata K., Neurobiol. Aging, 24, 745-752 (2003).
32. Hirata M., Mori T., Soga S., Umeda T., Ohmomo Y., Chem. Pharm. Bull., 54, 470-475 (2006).
33. Walker J. M., Bowen W. D., Goldstein S. R., Roberts A. H., Patrick S. L., Hohmann A. G., De Costa B. R., Brain Res., 581, 33-38 (1992).
34. Mclean S., Weber E., Neuroscience, 25, 259-269 (1988).
35. Wessiman A. D., Broussle E. P., London E. D., J. Chem. Neuroanat., 3, 347-354 (1989).
36. Sicar R., Nichtenhauser R., Ieni J. P., Zukin S. R., J. Pharmacol. Exp. Ther., 237, 681-688 (1986).